Beta-lactamase

Venatorx Pharmaceuticals Announces Positive Phase 1 Results for VNRX-7145

Retrieved on: 
Wednesday, July 28, 2021
Health, Science, Pharmaceutical, Research, Clinical trials, Chemical compounds, Organic compounds, Heterocyclic compounds, Beta-lactamase, Antibiotic, Beta-lactamase inhibitors, β-Lactamase inhibitor, Pharmacokinetics, Cefepime, VNRX-7145, Venatorx Pharmaceuticals, Inc., VNRX-7145, VENATORX PHARMACEUTICALS, INC.

Venatorx Pharmaceuticals today announced positive top line results for its Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial ( ClinicalTrials.gov NCT04243863 ) of VNRX-7145, a novel component of the investigational oral antibiotic combination product.

Key Points: 
  • Venatorx Pharmaceuticals today announced positive top line results for its Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial ( ClinicalTrials.gov NCT04243863 ) of VNRX-7145, a novel component of the investigational oral antibiotic combination product.
  • The Phase 1 study was a 2-part, first-in-human dose-ranging study to evaluate the safety and pharmacokinetics (PK) of escalating oral doses of VNRX-7145.
  • Venatorxs two lead antibacterial clinical-stage programs are intravenous (cefepime-taniborbactam) and oral (ceftibuten/VNRX-7145) broad-spectrum beta-lactam/beta-lactamase inhibitor combinations that are in Phase 3 and Phase 1, respectively.
  • In addition, Venatorx is in Phase 1 with its first antiviral compound (VNRX-9945), a Hepatitis B virus inhibitor.

Shionogi Announces In Vitro and Real-World Data Presented at ECCMID 2021 Demonstrating Activity of cefiderocol Against Critical Priority Gram-negative Bacterial Pathogens

Retrieved on: 
Thursday, July 8, 2021
Health, Clinical trials, Research, Pharmaceutical, Science, Biotechnology, Bacteria, Medical specialties, Moraxellaceae, Gram-negative bacteria, Pathogenic bacteria, Pseudomonadales, Beta-lactam antibiotics, Acinetobacter baumannii, Carbapenem, Acinetobacter, Beta-lactamase, Stenotrophomonas maltophilia

Cefiderocol also demonstrated broad activity against the isolates resistant to recently approved beta-lactam / beta-lactamase inhibitor combinations.

Key Points: 
  • Cefiderocol also demonstrated broad activity against the isolates resistant to recently approved beta-lactam / beta-lactamase inhibitor combinations.
  • Carbapenem-resistant A. baumannii (n=96; 40.5%) and carbapenem-resistant P. aeruginosa (n=78; 32.9%) were the most common pathogens.
  • Activity of Cefiderocol and Comparators against European Isolates of Pseudomonas aeruginosa, Acinetobacter baumannii-calcoaceticus species complex, and Stenotrophomonas maltophilia, including Carbapenem-Resistant Isolates.
  • The CARBAR part 1 study: a pooled analysis of the epidemiology data for UK, France and Spain: Bacterial susceptibility & resistance.

Qpex Biopharma Initiates Phase 1 Study of ORAvance™ for Oral Treatment of Drug-Resistant Gram-Negative Bacterial Infections

Retrieved on: 
Wednesday, May 12, 2021
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Beta-lactam antibiotics, β-lactam antibiotic, β-Lactamase inhibitor, Beta-lactamase, Biomedical Advanced Research and Development Authority, Beta-lactamase inhibitors, Antibiotics, Biocides, Drugs, Infectious diseases, Penicillins

The World Health Organization (WHO) has also prioritized development of new treatments for these pathogens.

Key Points: 
  • The World Health Organization (WHO) has also prioritized development of new treatments for these pathogens.
  • Two of the products use QPX7728, an ultra-broad-spectrum beta-lactamase inhibitor that restores the potency of beta-lactam antibiotics in vitro and in vivo.
  • Qpex\xe2\x80\x99s current collaboration with BARDA is focused on advancing a portfolio of novel antibiotics, including the QPX7728-based products OMNIvance and ORAvance.
  • For more information, please visit www.qpexbio.com and follow us on Twitter and LinkedIn .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210512005284/en/\n'

Worldwide Antibiotics Industry to 2026 - Featuring Pfizer, Bayer and Novartis Among Others

Retrieved on: 
Tuesday, March 30, 2021
Health sciences, Articles, Health, Beta-lactam antibiotics, Evolutionary biology, Pharmaceuticals policy, Veterinary medicine, Antimicrobial resistance, Antibiotic, Beta-lactamase, β-Lactamase inhibitor, Drug resistance

The Global Antibiotics Market size is expected to reach $62.5 billion by 2026, rising at a market growth of 5.3% CAGR during the forecast period.

Key Points: 
  • The Global Antibiotics Market size is expected to reach $62.5 billion by 2026, rising at a market growth of 5.3% CAGR during the forecast period.
  • Presently, the demand for beta-lactam and beta-lactamase inhibitors class of antibiotics is more among healthcare providers.
  • The antibiotics market is growing owing to the increasing consumption of antibiotics in middle and lower-income countries, huge investments in R&D activities by pharmaceutical companies, and the increasing number of infectious diseases.
  • Although, the development of antibiotic resistance and the rising cost of drug approval hinder the growth of the antibiotic market.

Global Antibiotics Market (2020 to 2026) - by Action Mechanism, Drug Class and Region - ResearchAndMarkets.com

Retrieved on: 
Friday, March 26, 2021
Health, Pharmaceutical, Health sciences, Health, Articles, Beta-lactam antibiotics, Evolutionary biology, Pharmaceuticals policy, Veterinary medicine, Beta-lactamase inhibitors, Antimicrobial resistance, β-Lactamase inhibitor, Antibiotic, Beta-lactamase

The "Global Antibiotics Market By Action Mechanism, By Drug Class, By Region, Industry Analysis and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Antibiotics Market By Action Mechanism, By Drug Class, By Region, Industry Analysis and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com's offering.
  • The Global Antibiotics Market size is expected to reach $62.5 billion by 2026, rising at a market growth of 5.3% CAGR during the forecast period.
  • Presently, the demand for beta-lactam and beta-lactamase inhibitors class of antibiotics is more among healthcare providers.
  • Although, the development of antibiotic resistance and the rising cost of drug approval hinder the growth of the antibiotic market.

Qpex Biopharma Initiates Phase 1 Clinical Trial of QPX7728 for Drug-Resistant Bacterial Infections

Retrieved on: 
Thursday, December 3, 2020
Biotechnology, Pharmaceutical, General Health, Health, Infectious diseases, Hospitals, Clinical trials, Other Health, Chemical compounds, Organic compounds, β-Lactamase inhibitor, Chemistry, Beta-lactamase, Beta-lactamase inhibitors, Antibiotics, β-lactam antibiotic, Beta-lactam, Carboxylic acids, Drug resistance, Discovery and development of cephalosporins, QPX7728, Biomedical Advanced Research and Development Authority (BARDA) Partnership, Brii Biosciences Partnership, Antimicrobial Resistance (AMR), Qpex Biopharma

Today marks another important milestone for Qpex as we begin advancing three novel product candidates into clinical trials during the coming months, said Michael Dudley, Pharm.D., president and chief executive officer of Qpex Biopharma.

Key Points: 
  • Today marks another important milestone for Qpex as we begin advancing three novel product candidates into clinical trials during the coming months, said Michael Dudley, Pharm.D., president and chief executive officer of Qpex Biopharma.
  • We believe that QPX7728 has demonstrated a preclinical profile that exceeds that of recently marketed beta-lactamase inhibitors, as well as those in ongoing clinical trials.
  • Beta-lactamases are bacterial enzymes that destroy beta-lactam antibiotics and are the major mechanism of resistance to these drugs in gram-negative bacteria.
  • Qpex has a multi-product collaboration with Brii Biosciences for the development and commercialization of three of its products in greater China.

Venatorx Pharmaceuticals to Present Data on Cefepime-Taniborbactam at IDWeek 2020

Retrieved on: 
Wednesday, October 21, 2020
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Infectious diseases, Clinical trials, Bacteria, Gram-negative bacteria, Chemical compounds, Organic compounds, Enterobacteriaceae, Beta-lactam antibiotics, Beta-lactamase, Antibiotic-resistant bacteria, Carbapenem, Thiazoles, Pseudomonas aeruginosa, Cefepime, Cefepime-Taniborbactam, Venatorx Pharmaceuticals, Inc.

When combined with cefepime, a fourth generation cephalosporin antibiotic, taniborbactam drives antimicrobial activity against gram-negative bacteria including carbapenemase-producing-Enterobacterales and Pseudomonas aeruginosa including multi-drug resistance strains.

Key Points: 
  • When combined with cefepime, a fourth generation cephalosporin antibiotic, taniborbactam drives antimicrobial activity against gram-negative bacteria including carbapenemase-producing-Enterobacterales and Pseudomonas aeruginosa including multi-drug resistance strains.
  • This includes pathogens that produce extended-spectrum beta-lactamases, AmpC beta-lactamases, AmpC, KPC, OXA, NDM, and VIM.
  • Venatorx is currently enrolling a Phase 3 clinical trial ( ClinicalTrials.gov NCT03840148 ) of cefepime-taniborbactam in patients with complicated urinary tract infections (cUTIs).
  • Venatorx Pharmaceuticals is a private pharmaceutical company focused on improving health outcomes for patients with multi-drug-resistant bacterial infections and hard-to-treat viral infections.

BiomX Presents Preclinical Data on Phage Targeting Multidrug Resistant Klebsiella pneumoniae Bacteria at the Infectious Disease Society of America (IDSA) IDWeek Conference 2020

Retrieved on: 
Wednesday, October 21, 2020
Research, Infectious diseases, Clinical trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Bacteria, Microbiology, Gram-negative bacteria, Bacteriology, Enterobacteriaceae, Pathogenic bacteria, Beta-lactam antibiotics, Klebsiella pneumoniae, Polysaccharide encapsulated bacteria, Carbapenem, Beta-lactamase, Phage therapy

BiomX Inc. (NYSE American : PHGE), a clinical stage company developing natural and engineered phage therapies that target specific pathogenic bacteria, today presented preclinical data from its phage panel for the treatment of inflammatory bowel disease at the Infectious Disease Society of America (IDSA) Infectious Disease Week (IDWeek) 2020 conference.

Key Points: 
  • BiomX Inc. (NYSE American : PHGE), a clinical stage company developing natural and engineered phage therapies that target specific pathogenic bacteria, today presented preclinical data from its phage panel for the treatment of inflammatory bowel disease at the Infectious Disease Society of America (IDSA) Infectious Disease Week (IDWeek) 2020 conference.
  • The poster presentation details a phage therapy panel, comprised of phage directed against Klebsiella pneumoniae, showing a broad target host range and the potential to address carbapenem-resistant and extended spectrum beta-lactamase (ESBL)-producing bacteria.
  • The World Health Organization classifies carbapenem-resistant and ESBL-producing Enterobacteriaceae, which include Klebsiella pneumoniae, as a critical threat, the highest threat level.
  • For example, when BiomX discusses its phage therapy panel showing a broad target host range and the potential to address carbapenem-resistant and ESBL-producing bacteria, BiomX is making forward-looking statements.

Shionogi Announces Publication of Two Studies in the Lancet Infectious Diseases Highlighting the Efficacy and Safety of Cefiderocol for the Treatment of Infections Due to Aerobic Gram-negative Bacteria in Adults With Limited Treatment Options

Retrieved on: 
Tuesday, October 13, 2020
Health, Infectious diseases, Hospitals, Clinical trials, Pharmaceutical, Biotechnology, Medicine, Health, Clinical medicine, Cefiderocol, Siderophores, Healthcare-associated infections, Medical terminology, Beta-lactamase, Acinetobacter, Combination therapy

BAT was combination therapy in 71% (27/38) of cases with 28 different BAT regimens being used, whereas 83% (66/80) of cefiderocol treatment was monotherapy.

Key Points: 
  • BAT was combination therapy in 71% (27/38) of cases with 28 different BAT regimens being used, whereas 83% (66/80) of cefiderocol treatment was monotherapy.
  • The clinical and microbiological outcomes were generally similar between cefiderocol and BAT, except for metallo-beta-lactamases infections where cefiderocol was substantially better (cefiderocol: 75% and 44%; BAT: 29% and 14%, respectively).
  • There was an observed mortality difference between treatment arms in the subset of patients with Acinetobacter spp.
  • Cefiderocol received European Commission (EC) marketing authorisation for the treatment of infections due to aerobic Gram-negative bacteria in adults with limited treatment options under the brand name FETCROJA in April 2020 and is now commercially available in the UK.

Collaborative Research by OpGen Group Company Ares Genetics and Johns Hopkins Researchers Demonstrates Potential of Next-Generation Sequencing for Investigation of Genetic Antimicrobial Resistance Mechanisms and Molecular Susceptibility Testing

Retrieved on: 
Wednesday, September 16, 2020
Articles, Branches of biology, Beta-lactam antibiotics, Drugs, Ceftolozane/tazobactam, Beta-lactamase inhibitors, Tazobactam, Beta-lactamase, Antimicrobial resistance, DNA sequencing, Pseudomonas aeruginosa, Karen Bush

To overcome antimicrobial resistance, ceftolozane-tazobactam has been introduced as a novel -lactam--lactamase inhibitor combination agent and received initial U.S. FDA approval in 2014.

Key Points: 
  • To overcome antimicrobial resistance, ceftolozane-tazobactam has been introduced as a novel -lactam--lactamase inhibitor combination agent and received initial U.S. FDA approval in 2014.
  • Findings demonstrate the potential of Next-Generation Sequencing (NGS) to investigate mechanisms of resistance by analyzing whole-genome sequencing data from P. aeruginosa isolates that developed resistance under treatment with ceftolozane-tazobactam.
  • The researchers propose extending ceftolozane-tazobactam infusions as a potential protective measure against acquired mutational resistance.
  • The present study is the result of an ongoing collaboration between Ares Genetics and the Johns Hopkins University School of Medicine, with the goal of investigating the diagnostic potential of NGS for antimicrobial susceptibility testing.